The official project term of NAPKON 2.0 as part of the NUM ended on 31 December 2024. However, the publication and analysis of data and biosamples will continue, and the knowledge gained will form a solid basis for future projects and scientific collaborations.
NAPKON in figures: A remarkable balance sheet
With a total of 7,097 patients in the three cohorts SÜP, HAP and POP and 77 participating study centres, including 40 non-university sites, NAPKON has created a unique research network. The extensive data collection includes > 10,000 different data elements and > 20 standardised instruments to assess quality of life and health status. This was made possible by the impressive commitment of over 1,500 participants from medicine, research and infrastructure.
Outlook: Continuation and new initiatives
The valuable experience gained from NAPKON is now being channelled into follow-up projects: The POP cohort will be continued from 2025 in the BMG-funded COVIDOM+ project. The data and biosamples obtained so far, including many unique OMICs data sets, will continue to be available for application. At the same time, the NUM study network is a pioneering platform for clinical and clinical-epidemiological studies that builds on the infrastructures of NAPKON, NUKLEUS and the NUM Data Integration Centres. The first integrated specialist network for infections has already been established, and further specialist networks will follow. The two specialist networks for stroke and intensive care medicine are specifically planned.
More information: https://napkon.de/